Gilead Sciences Buy or Sell Recommendation

Macroaxis provides Gilead Sciences Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Gilead Sciences positions. The advice algorithm takes into account all of Gilead Sciences Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Gilead Sciences buy-and-hold prospective. Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice

Gilead Sciences Recommendation

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Gilead Sciences Inc is 'Strong Hold'.
For the selected time horizon Gilead Sciences Inc has a risk adjusted performance of (0.08), jensen alpha of (0.11), total risk alpha of (0.04), sortino ratio of 0.0 and treynor ratio of (0.34)
Macroaxis provides unbiased buy or sell recommendations on Gilead Sciences that should be used to complement current analysts and expert consensus on Gilead Sciences. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Gilead Sciences Inc is not overpriced, please check out all Gilead Sciences fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Gilead Sciences has Number of Shares Shorted of 15.82 M, we strongly advise you confirm Gilead Sciences market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return-0.12Value At Risk-1.5547
Potential Upside0.9852Standard Deviation0.8072
 Return Density 
Benchmark  Embed    Distribution 

Institutional Investors

Security TypeSharesValue
Vanguard Group IncCommon Shares84.5 M6.1 B
State Street CorpCommon Shares60.4 M4.3 B
Fmr LlcCommon Shares39.1 M2.8 B
Blackrock Institutional Trust Company NaCommon Shares36.9 M2.6 B
Blackrock Fund AdvisorsCommon Shares28.5 M2 B
Bank Of New York Mellon CorpCommon Shares27.8 M2 B
Capital Research Global InvestorsCommon Shares24.8 M1.8 B

Gilead Sciences Greeks

Alpha over NYSE
βBeta against NYSE= 0.38 
Overall volatility
= 0.78 
 IrInformation ratio =(0.08) 

Gilead Sciences Volatility Alert

Gilead Sciences Inc exhibits ver low volatility with skewness of -0.56 and kurtosis of -0.12. However, we advise investors to further study Gilead Sciences Inc technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Gilead Sciences to competition
FundamentalsGilead SciencesPeer Average
Return On Equity0.85 % (15.17) %
Return On Asset0.22 % (15.64) %
Profit Margin0.48 % (5.50) %
Operating Margin60.93 % (10.91) %
Current Valuation6.82 B152.14 B
Shares Outstanding1.56 B1.43 B
Shares Owned by Insiders0.60 % 6.91 %
Shares Owned by Institutions83.40 % 18.37 %
Number of Shares Shorted15.82 M3.24 M
Price to Earning6.77 times40.69 times
Price to Book5.75 times14.44 times
Price to Sales3.06 times17.81 times
Revenue466.79 M9.85 B
Gross Profit397.07 M21.75 B
EBITDA19.22 B1.41 B
Net Income72.1 M517.71 M
Cash and Equivalents616.93 M3.89 B
Cash per Share9.31 times5.17 times
Total Debt595.47 M7.36 B
Debt to Equity1.56 times0.72 times
Current Ratio1.94 times3.30 times
Book Value Per Share14.36 times13.64 times
Cash Flow from Operations74.41 M1.25 B
Short Ratio1.65 times2.09 times
Earnings Per Share10.82 times2.30 times
Price to Earnings To Growth(2.77) times1.22 times
Number of Employees8 K10.67 K
Market Capitalization6.69 B29.78 B
Total Asset1.29 B126.86 B
Retained Earnings18.15 B38.24 B
Working Capital1.08 B3.58 B
Current Asset1.18 B36.8 B
Strong Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Sale by Norbert Bischofberger of 6427 shares of Gilead Sciences [view details]
Risk Adjusted Performance(0.08)
Market Risk Adjusted Performance(0.33)
Mean Deviation0.6225
Coefficient Of Variation(670.71)
Standard Deviation0.8072
Information Ratio(0.08)
Jensen Alpha(0.11)
Total Risk Alpha(0.04)
Treynor Ratio(0.34)
Maximum Drawdown2.86
Value At Risk(1.55)
Potential Upside0.9852
Current Valuation
Gilead Sciences Current Valuation Analysis
Gilead Sciences Inc is rated below average in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is currently estimated at about 137.03 Billion. Gilead Sciences holds roughly 6.82 Billion in current valuation claiming about 5% of equities listed under Pharmaceuticals And Biosciences industry.